Stockreport

Is Teva Pharma's Restructuring Plan Actually 'More Reasonable'? [Investor's Business Daily]

Dr. Reddy's Laboratories Ltd  (RDY) 
US:NYSE Investor Relations: drreddys.com/investors
PDF Technology Related news 12:32 PM ET Regeneron should benefit after Novartis and Roche presented data for competitors to blockbuster eye drug Eylea. IBD Rating Upgrade [Read more]